Nolasiban - ObsEva

Drug Profile

Nolasiban - ObsEva

Alternative Names: Erlosiban; OBE-001

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female infertility
  • Phase II Preterm labour

Most Recent Events

  • 09 Mar 2018 ObsEva plans a phase III trial for Female infertility in USA, by the end of 2018
  • 26 Feb 2018 Efficacy and safety data from the phase III IMPLANT2 trial in Female infertility released by ObsEva
  • 01 Aug 2017 ObsEva completes enrolment in a phase III clinical trial in Female infertility in Belgium, Denmark, Estonia, Finland, Germany, Hungary, Poland, Spain and Ukraine (PO) (EudraCT2016-004266-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top